H1 2022 Financial performance (growth numbers and commentary at CER)
‒ Total Revenue increased 48% to $22,161m, with growth coming from all disease areas and from the addition
of Alexion
‒ Total Revenue from Oncology increased 22%5
, including receipt of a milestone payment. Product Sales from
Oncology increased 18%. Total Revenue from R&I6
increased 3%, CVRM7
increased 19%8 and Rare
Disease increased 10%8
. Excluding a one-off historical pricing adjustment, Rare Disease increased 8%
‒ Core Gross Margin of 81%, with the second quarter benefitting from currency fluctuations, and phasing of
COVID-19 medicine contracts
‒ Core Operating Margin of 33%. Core Total Operating Expense increased 33%, reflecting the addition of
Alexion, and continued investment in new launches and the pipeline to build industry-leading mid-to-long
term growth
‒ Core EPS of $3.61, with the second quarter benefitting from a Core Tax Rate of 15%. The FY 2022
expectation for the Core Tax Rate remains 18-22%
‒ Interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share, reflecting the Board’s intent
to increase to $2.90 in FY 2022, as announced at FY 2021
‒ FY 2022 Total Revenue guidance at CER increased due to an updated outlook for COVID-19 medicines and
continued strong performance of the overall business, enabling further investment in the pipeline. With an
expectation that Other Operating Income in H2 2022 will be similar to H1 2022, EPS guidance is unchanged.
The record date for the first interim dividend for 2022, payable on 12 September 2022, will be 12 August 2022.
The ex-dividend date will be 11 August 2022
https://www.astrazeneca.com/content/dam ... cement.pdf
RNS here; https://www.investegate.co.uk/astrazene ... 00111686U/
Ian.